A 63-year-old retiree with $400,000 parked in the Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) likely picked it for the 100-stock screen and the reliable income stream. The top 10 positions now make up 41% of the fund, which means roughly $164,000 of that nest egg sits in ten names. For a fund managing $94 billion, SCHD’s concentration profile deserves a closer look before anyone treats it as a one-ticker solution.
The strategy and the income engine
SCHD tracks the Dow Jones U.S. Dividend 100 Index, screening for companies with at least 10 consecutive years of dividend increases and strong balance sheets. The return engine is simple: collect dividends from mature, cash-generative blue chips and let the index reconstitute once a year in March. Investors get a current yield of 3.27% at a 0.06% expense ratio, among the cheapest in the category.
The screen has a real edge for retirees, as names like Merck (NYSE:MRK | MRK Price Prediction) raised its quarterly payout from $0.77 in 2024 to $0.85 in early 2026, and Bristol Myers Squibb (NYSE:BMY) nudged its quarterly dividend from $0.62 to $0.63 over the same window. Steady raises at the holding level translate into a stable income floor at the fund.
Heavier than the S&P 500 at the top
The top 10 names carry individual weights between around 3%: Qualcomm leads, followed by Texas Instruments, UnitedHealth, Chevron, Coca-Cola, ConocoPhilips, Verizon, and Amgen. The combined reading of the top stocks is heavier than the S&P 500’s 36% top-10 concentration, even though the headline index is famously crowded at the top with mega-cap tech.
On the other hand, sector tilts compound the issue. Energy sits near 16% after the March 2026 reconstitution trimmed it from 24%, with two oil majors in the top five. Healthcare runs roughly 18%, anchored by three drug makers. Single-stock risk inside SCHD runs higher than the 100-name headcount suggests.
Does it deliver?
Over the past year, SCHD returned 29%, edging out SPY’s 27% as the rotation into value lifted dividend names. Stretch the window, and the picture flips. SCHD’s five-year total return of 50% trails SPY’s 79% by nearly 30 percentage points. That gap is the price an SCHD owner paid for skipping the AI-led rally between 2023 and 2025. Over ten years, SCHD’s 233% still lags SPY’s 258%, though by a narrower margin.
The tradeoffs
- Concentration drift between reconstitutions. March is the only month when weights reset. A buyer in October owns a different fund than one buying in April, with the top names having drifted meaningfully in the interim.
- Sector cyclicality. Heavy energy and healthcare weights mean oil prices and drug-pricing politics move the fund disproportionately versus a broad index.
- Growth opportunity cost. The dividend screen excludes most mega-cap tech, the dominant return source for nearly a decade of U.S. equity history.
Where SCHD fits, and where to pair it
SCHD serves as an income-anchored core holding for retirees seeking yield and quality screening at near-zero cost. Capping it at 30%-40% of the equity sleeve is sensible given the top-10 weight. The Vanguard High Dividend Yield ETF (NYSEARCA:VYM) holds roughly 620 names, with a top-10 concentration of near 24%, and has returned 69% over five years. The iShares Core Dividend Growth ETF (NYSEARCA:DGRO) features Apple, Microsoft, and Broadcom at the top, providing the tech overlap SCHD lacks. Pairing SCHD with either flattens single-stock risk without abandoning the income mandate that drew the 63-year-old to the fund in the first place.
Top Gaining Stocks
Top Losing Stocks